DEXAMETAZONA ROMPHARM 4 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dexametazona rompharm 4 mg/ml

rompharm company s.r.l. - romania - dexamethasonum - sol. inj. - 4mg/ml - corticosteroizi sistemici glucocorticoizi

DEXAMETAZONA KRKA 4 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dexametazona krka 4 mg

krka, d.d., novo mesto - slovenia - dexamethasonum - compr. - 4mg - corticosteroizi sistemici glucocorticoizi

DEXAMETAZONA KRKA 8 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dexametazona krka 8 mg

krka, d.d., novo mesto - slovenia - dexamethasonum - compr. - 8mg - corticosteroizi sistemici glucocorticoizi

DEXAMED 8 mg/2 ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dexamed 8 mg/2 ml

medochemie ltd. (factory b) - cipru - dexamethasonum - sol. inj. - 8mg/2ml - corticosteroizi sistemici glucocorticoizi

Onureg Uniunea Europeană - română - EMA (European Medicines Agency)

onureg

bristol-myers squibb pharma eeig - azacitidină - leucemie, mieloidă, acută - agenți antineoplazici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Ronapreve Uniunea Europeană - română - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - seruri imune și imunoglobuline, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. vezi secțiunile 4. 4 și 5.